FDA again re­quests com­ments on ni­trosamine im­pu­ri­ties in drugs

As the phar­ma in­dus­try con­tin­ues to grap­ple with the iden­ti­fi­ca­tion and con­trol of im­pu­ri­ties known as ni­trosamines in drugs, the FDA is once again seek­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER